Neutrophil-lymphocyte ratio as a predictor of oncologic outcomes in stage IVB, persistent, or recurrent cervical cancer patients treated by chemotherapy

Table 3 Multivariate analysis for independent factors associated with response rate, progression free survival and overall survivals in 355 cervical cancer patients (only significant results were shown)

Variables	Overall response rate		Progression free survival		Overall survival
Variables	OR (95% CI)	P	HR (95% CI)	P	HR (95% CI)	P
Body mass index, kg/m²
< 18.5	2.064 (1.267–3.364)	0.004	–		–
18.5–24.9	2.165 (1.051–4.461)	0.036
≥ 25	reference
Histopathology
Non-SCC	–		reference		reference
SCC			1.334 (1.060–1.678)	0.014	1.533 (1.034–2.272)	0.034
Disease sites before chemotherapy initiation
Locoregional	–		reference		reference
Distant metastasis			1.315 (1.042–1.660)	0.021	2.008 (1.319–3.056)	0.001
Neutrophil count, /mm³
≤ 7000	–		–		reference
> 7000					1.821 (1.139–2.910)	0.012
NLR
< 3.6	reference		reference		reference
≥ 3.6	1.642 (1.048–2.572)	0.030	1.676 (1.334–2.107)	< 0.001	2.544 (1.672–3.870)	< 0.001
Platelet count, /mm³
≤ 400,000	–		reference		reference
> 400,000			1.334 (1.060–1.678)	0.014	1.633 (1.078–2.474)	0.021

CI confidence interval, HR hazard ratio, NLR neutrophil-lymphocyte ratio, OR odds ratio, SCC squamous cell carcinoma

ISSN: 1471-2407